NASDAQ:SLP - Simulations Plus Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $83.00
  • Forecasted Upside: 28.05 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$64.82
▼ -1.83 (-2.75%)
1 month | 3 months | 12 months
Get New Simulations Plus Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SLP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SLP

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$83.00
▲ +28.05% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Simulations Plus in the last 3 months. The average price target is $83.00, with a high forecast of $95.00 and a low forecast of $75.00. The average price target represents a 28.05% upside from the last price of $64.82.
Buy
The current consensus among 3 polled investment analysts is to buy stock in Simulations Plus.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/10/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/8/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/6/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/4/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/4/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/2/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/1/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/31/2020

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/16/2020Raymond JamesInitiated CoverageOutperform$95.00Low
i
9/8/2020OppenheimerInitiated CoverageOutperform$79.00High
i
7/10/2020Craig HallumBoost Price TargetBuy$56.00 ➝ $75.00High
i
6/8/2020Craig HallumBoost Price TargetBuy$40.00 ➝ $56.00Low
i
1/6/2020Craig HallumInitiated CoverageBuy$40.00High
i
1/16/2019Taglich BrothersDowngradeBuy ➝ Speculative BuyMedium
i
Rating by H. Halpern at Taglich Brothers
(Data available from 10/31/2015 forward)
Simulations Plus logo
Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation, and machine-learning-based prediction of properties of molecules from their structure worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments that measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments. It also provides PKPlus, a standalone program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for NCA and compartmental PK modelling; ADMET Predictor, a chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher. In addition, it offers MedChem Studio, a software tool for data mining and designing new molecules; KIWI, a cloud-based Web application to organize, process, maintain, and communicate the volume of data and results generated by pharmacologists and scientists over the duration of a drug development program; DILIsym, a quantitative systems pharmacology software; NAFLDsym, a simulation program for analyzing nonalcoholic fatty liver disease; and RENAsym for investigating and predicting drug-induced or acute kidney injury. Further, the company provides population modeling and simulation contract research services for the pharmaceutical and biotechnology industries; and clinical-pharmacology-based consulting services in support of regulatory submissions. It sells its pharmaceutical/chemistry software to pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies. The company was founded in 1996 and is headquartered in Lancaster, California.
Read More

Today's Range

Now: $64.82
$64.23
$66.47

50 Day Range

MA: $69.35
$62.83
$77.18

52 Week Range

Now: $64.82
$26.00
$77.89

Volume

172,165 shs

Average Volume

213,429 shs

Market Capitalization

$1.16 billion

P/E Ratio

129.64

Dividend Yield

0.36%

Beta

N/A